NNE Stock: $569M cash, but where is revenue?
Nano Nuclear Energy has cash, a KRONOS MMR NRC review milestone, and a nuclear logistics acquisition, but investors still need revenue proof.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
10Results9Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
NUSCALE POWER Corp (SMR)
SEC filings, financial facts, source resources, and Goglides workspace context for NUSCALE POWER Corp.
OpenNuScale Power Update: Evaluating Small Modular Reactors Against Increasing Data Center Demand
Small modular reactors sound like a data-center power answer, but NuScale still has to prove commercialization.
OpenAethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clock
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAGMB: the IPO biotech with two fibrosis readouts before its runway clock matters
AgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenAdagio Medical: the $12.9M cash clock behind a make-or-break VT filing
Adagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.
OpenAcurx: the CDI antibiotic bet racing a cash clock
Acurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution become
OpenActuate Therapeutics: the survival signal with a July cash wall
Actuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAcrivon Therapeutics: the cancer-data story with a 2026 readout clock
Acrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.
OpenAclaris Therapeutics: the three-shot catalyst stack racing the cash clock
Aclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
Open